Syros Pharmaceuticals Inc (SYRS):企業の財務・戦略的SWOT分析

◆英語タイトル:Syros Pharmaceuticals Inc (SYRS) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH471308FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company offers its pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that is used to treat patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and SY-1365, a potent and selective small molecule inhibitor of CDK7 that is used to treat patients with transcriptionally driven solid tumors and acute leukemias. Syors provides gene regulation, new medicines development, proprietary drug development platform, and integrated gene control assay technologies. Its gene control platform identifies novel gene control targets linked to genomically defined patient populations, and drugging gene control targets. The company partners with other biopharmaceutical companies to extend the potential of our gene control platform across multiple therapeutic areas and diseases. Syros is headquartered in Cambridge, Massachusetts, the US.

Syros Pharmaceuticals Inc Key Recent Developments

Mar 04,2021: Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Feb 25,2021: Syros to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 4, 2021
Jan 11,2021: Syros announces strategic priorities and expected milestones
Jan 07,2021: Syros to Present at 39th Annual J.P. Morgan Healthcare Conference
Nov 05,2020: Syros Pharmaceuticals reports third quarter 2020 financial results and highlights key accomplishments and upcoming milestones

This comprehensive SWOT profile of Syros Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Syros Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Syros Pharmaceuticals Inc – Key Information
Syros Pharmaceuticals Inc – Overview
Syros Pharmaceuticals Inc – Key Employees
Syros Pharmaceuticals Inc – Key Employee Biographies
Syros Pharmaceuticals Inc – Key Operational Heads
Syros Pharmaceuticals Inc – Major Products and Services
Syros Pharmaceuticals Inc – History
Syros Pharmaceuticals Inc – Company Statement
Syros Pharmaceuticals Inc – Locations And Subsidiaries
Syros Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Syros Pharmaceuticals Inc – Business Description
Syros Pharmaceuticals Inc – Corporate Strategy
Syros Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
Syros Pharmaceuticals Inc – Strengths
Syros Pharmaceuticals Inc – Weaknesses
Syros Pharmaceuticals Inc – Opportunities
Syros Pharmaceuticals Inc – Threats
Syros Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Syros Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Syros Pharmaceuticals Inc, Key Information
Syros Pharmaceuticals Inc, Key Ratios
Syros Pharmaceuticals Inc, Share Data
Syros Pharmaceuticals Inc, Major Products and Services
Syros Pharmaceuticals Inc, History
Syros Pharmaceuticals Inc, Key Employees
Syros Pharmaceuticals Inc, Key Employee Biographies
Syros Pharmaceuticals Inc, Key Operational Heads
Syros Pharmaceuticals Inc, Other Locations
Syros Pharmaceuticals Inc, Subsidiaries
Syros Pharmaceuticals Inc, Key Competitors
Syros Pharmaceuticals Inc, SWOT Analysis
Syros Pharmaceuticals Inc, Ratios based on current share price
Syros Pharmaceuticals Inc, Annual Ratios
Syros Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Syros Pharmaceuticals Inc (SYRS):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Blue Cross Blue Shield of Michigan:企業の戦略・SWOT・財務情報
    Blue Cross Blue Shield of Michigan - Strategy, SWOT and Corporate Finance Report Summary Blue Cross Blue Shield of Michigan - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Phatra Leasing Public Company Ltd (PL):企業の財務・戦略的SWOT分析
    Phatra Leasing Public Company Ltd (PL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Bon Secours Health System Inc:企業の戦略的SWOT分析
    Bon Secours Health System Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Tianjin Chase Sun Pharmaceutical Co Ltd (300026):企業の財務・戦略的SWOT分析
    Summary Tianjin Chase Sun Pharmaceutical Co Ltd (Chase Sun) is a medicine and health industry group. The company research, develops, produces, and markets various pharmaceutical products. It offers products such as Chinese herb preparations, Chinese medicinal granules, synthetic drugs, biotech drugs …
  • The Talbots, Inc.:企業の戦略的SWOT分析
    The Talbots, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Eiffage SA (FGR):電力:M&Aディール及び事業提携情報
    Summary Eiffage SA (Eiffage) is a construction and concession company. It operates in businesses of energy and infrastructure construction, real estate development, road construction, civil engineering, concessions, and public-private partnerships. The company’s activities include construction, reno …
  • Jubilant Life Sciences Ltd (JUBILANT):製薬・医療:M&Aディール及び事業提携情報
    Summary Jubilant Life Sciences Ltd (Jubilant) is an integrated pharmaceutical and life sciences company that provides pharmaceuticals, life science ingredients and drug discovery solutions. The company’s product portfolio includes radiopharmaceuticals, allergy therapy products, active pharmaceutical …
  • J.F. Shea Co Inc:企業の戦略・SWOT・財務情報
    J.F. Shea Co Inc - Strategy, SWOT and Corporate Finance Report Summary J.F. Shea Co Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Central Electricity Generating Co:企業の戦略的SWOT分析
    Central Electricity Generating Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • Luxottica Group S.p.A.:企業の戦略・SWOT・財務情報
    Luxottica Group S.p.A. - Strategy, SWOT and Corporate Finance Report Summary Luxottica Group S.p.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • GridPoint, Inc.-エネルギー分野:企業M&A・提携分析
    Summary GridPoint, Inc. (Gridpoint), a subsidiary of Twenty First Century Utilities LLC, is a provider of data-driven energy management systems. The company offers a wide range of energy management hardware including control, equipment-level sub-metering and advanced monitoring devices such as contr …
  • Boart Longyear Ltd:企業の戦略・SWOT・財務分析
    Boart Longyear Ltd - Strategy, SWOT and Corporate Finance Report Summary Boart Longyear Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Fuji Electric Co., Ltd.:企業の戦略・SWOT・財務情報
    Fuji Electric Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Fuji Electric Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Lassila & Tikanoja plc:企業のM&A・事業提携・投資動向
    Lassila & Tikanoja plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Lassila & Tikanoja plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Medikit Co Ltd (7749):企業の財務・戦略的SWOT分析
    Summary Medikit Co Ltd (Medikit) is a medical equipment provider that offers vascular devices. The company offers IV catheter, hemodialysis and intervention products. Its products include supercath Z3V, supercath 5 safety IV catheter, supercath AZ, supercath CLS, i-works, seiha, parent plus, parent …
  • Merrimack Pharmaceuticals Inc (MACK):企業の財務・戦略的SWOT分析
    Merrimack Pharmaceuticals Inc (MACK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Sygnis AG (LIO1):医療機器:M&Aディール及び事業提携情報
    Summary Sygnis AG (Sygnis), formerly Sygnis Pharma AG is a developer of novel products and tools in the field of molecular biology. The company undertakes development and marketing of new molecular biological technologies for DNA amplification and sequencing. Its offers products such as single cell …
  • Haisco Pharmaceutical Group Co Ltd (002653):医療機器:M&Aディール及び事業提携情報
    Summary Haisco Pharmaceutical Group Co Ltd (Haisco Pharma), formerly Xizang Haisco Pharmaceutical Group Co Ltd is a developer and marketer of chemical drug preparations. The company offers parenteral nutrition drugs, first-aid drugs, antibiotics, anesthetic agents, nervous system drugs, digestive sy …
  • Scottish Power Ltd:企業の発電所・SWOT分析2018
    Scottish Power Ltd - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees …
  • Kemwell Biopharma Pvt Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Kemwell Biopharma Pvt Ltd (Kemwell) formerly Kemwell Pvt Ltd a subsidiary of Recipharm AB is a healthcare solutions provider that offers product development and manufacturing solutions. The organization provides contract pharmaceutical development and manufacturing organization and concentra …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆